Telesis Bio, Inc (TBIO) - Earnings per share increase in current year
Telesis Bio, Inc. (TBIO) demonstrates potential through the automation of mRNA and DNA synthesis in the era of gene therapy. The GURU.Markets service features a linear chart where the annual EPS change reaches 0.00, visualizing profit dynamics. The brand is valued for accelerating laboratory research via BioXp, while financial stability is based on regular sales of consumable cartridges amid muted demand for equipment.
Comprehensive metric breakdowns and analytics for Telesis Bio, Inc. (TBIO)
- current quotes and average value forecast:
- market capitalization indicators:
- business book valuation details:
- debt burden and liquidity indicators:
Debt to Capital Telesis Bio, Inc.|TBIO - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital telesisbio.com|TBIO - Company Aggregate Debts|Debts to Net Assets Telesis Bio, Inc|TBIO - Company Long-Term Debt|Company Short-Term Indebtedness Telesis Bio|Quick Liquidity Indicator telesisbio.com
- earnings and valuation multiples information:
TBIO - Net Income|Company Profit Forecast Telesis Bio, Inc.|TBIO - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Telesis Bio, Inc|TBIO - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telesis Bio, Inc|TBIO - Operating profit EBITDA|Net earnings per share for the last four quarters Telesis Bio|TBIO - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months telesisbio.com|TBIO - Earnings growth in current year|Projected earnings per share growth rate for next year Telesis Bio, Inc.
- sales volume and revenue information:
Fundamental valuation:TBIO - Telesis Bio Inc.
Earnings per share (EPS) dynamics serve as a key indicator of operational efficiency and the business's capitalization potential. This metric measures the annual percentage change in net income, allowing for the identification of stagnation phases or accelerated cash flow growth. By analyzing the year-over-year percentage change in EPS, an investor can assess the extent to which Telesis Bio (TBIO) gene synthesis system sales translate into actual financial results.
Main competitors
TEM - Expected net earnings per share growth this year|Net earnings per share growth this year QGEN|IONS: Earnings per share increase in current year|Earnings growth in current year RGEN|Earnings per share growth in current year RNA (aviditybiosciences.com)|Earnings growth in current year CRSP (CRISPR Therapeutics)|Expected net earnings per share growth this year GeneDx Holdings (WGS)|RARE - Earnings per share growth in current year|Earnings per share growth rate in current year Beam Tx|SRPT (Sarepta Therapeutics, Inc.) - Net earnings per share growth this year|twistbioscience.com - Earnings per share increase in current year|TXG (10x Genomics) - Earnings growth in current year|Intellia Therapeutics Inc (NTLA) - Expected net earnings per share growth this year|Earnings per share growth in current year Stoke (STOK)|BioLife - Earnings per share growth this year|Earnings growth in current year WVE (Wave Life Sciences)|MAZE - Net earnings per share growth this year|SION: Net earnings per share growth this year|Expected net earnings per share growth this year Prime Medicine Inc PRME|TSHA (Taysha) - Net earnings per share growth this year|QURE: Net earnings per one share growth for the current year|MGTX (MeiraGTx Holdings plc) - Earnings growth in current year|Earnings per share growth in current year RGNX|Earnings growth in current year SLDB|Expected net earnings per share growth this year Ocugen Inc|Earnings per share growth in current year Pacific Biosciences of California PACB|Benitec Corp (BNTC) - Earnings per share growth rate in current year|Design Therapeutics - Earnings growth in current year|RCKT (rocketpharma.com) - Earnings per share growth this year|4D Molecular Therapeutics, Inc. (FDMT) - Earnings per share growth in current year|Earnings per share growth this year LXEO|KRRO (Korro Bio Inc.) - Earnings growth in current year|Earnings growth in current year Editas Corp|Net earnings per share growth this year SLN (Silence Therapeutics)|Net earnings per one share growth for the current year PRQR|Earnings growth in current year CDXS (Codexis)|Sangamo Therapeutics Inc. (SGMO) - Earnings per share growth rate in current year|NAUT - Earnings per share growth in current year|MGX: Earnings per share growth in current year|DTIL: Earnings growth in current year|Earnings per share growth rate in current year Generation Bio (GBIO)|Earnings per share growth in current year Boundless Bio|Exicure Corp (XCUR) - Expected net earnings per share growth this year|Earnings growth in current year IMNN|Expected net earnings per share growth this year phiopharma.com|Earnings per share growth in current year Mustang Bio MBIO|Expected net earnings per share growth this year TransCode Therapeutics Inc. (RNAZ)|BNGO: Net earnings per share growth this year|Earnings per share increase in current year APDN (Applied DNA Sciences Inc)|BLUE: Earnings growth in current year|IPA (ImmunoPrecise Antibodies Ltd.) - Earnings per share growth in current year|OMGA (Omega Therapeutics) - Earnings growth in current year|singulargenomics.com (OMIC) - Expected net earnings per share growth this year|Earnings per share growth in current year Regulus Therapeutics Inc. (RGLS)|SYRS - Earnings per share growth rate in current year|TRACON - Net earnings per share growth this year|Earnings per share increase in current year UBX
